NEW YORK, NY / ACCESSWIRE / July 30, 2019 / WIMI is not only one of the leading providers in holographic advertising service, but also the operator in holographic entertainment in China. As shown in the F1 data of the WIMI published by SEC, the WIMI holographic platform realizes 6.6 billion displays through 2000 tags for 350 million users. In the past two years, WIMI made a total profit of over $23 million, quarterly net profit rose 68% on a year-on-year basis, and a profitable growth space has been opened. With the development of 5G holographic communication, the holographic cloud industry in which WIMI is engaged will grow explosively.

It is reported by the chtone, a financial app, WIMI was founded in 2015, which is a company that entered the VR/AR industry relatively earlier in the country, thus it has a certain first mover advantages. By 2018, the number of WIMI customers was 485, the number of holographic AR patents was 242, the number of holographic AR content was 4654, and the number of software copyright was 147, all of which widened a big gap with that of the second place. * Source: U.S. SEC – FORM F-1, WiMi Hologram Cloud Inc., Securities and Exchange Commission (SEC).

For the past few years, the application market of face recognition industry has been expanding. In order to obtain better accuracy and quality, the application of facial recognition shows the trend of transition from two-dimensional technology to three-dimensional technology. The reason for this trend is that two-dimensional facial recognition technology is easily affected by posture, light, appearance and other factors, thus reducing the recognition rate. Therefore, WIMI believes that three-dimensional technology will gradually replace three-dimensional facial recognition technology. It plans to provide 3D facial recognition of holographic cloud application service through artificial intelligence based on algorithm. The future plan of WIMI is to meet the needs of potential customers in various industries, such as home, retail, tourism, telecommunications, finance, national security, robotics, education, social media, terminal equipment, business, transportation, intelligent commerce or other potential applications, through the 3D facial recognition of holographic cloud technology.

As shown in IPO prospectus, with the change of bandwidth conditions of 5G holographic communication network, the market of 5G holographic application will be ushered in the explosive way, such high-end applications as holographic interactive entertainment, holographic conference and holographic press conference will gradually popularize to the direction of holographic social contace, holographic communication, holographic navigation, holographic home applications and so on. Based on such core technology as holographic AI face recognition technology and holographic AI DeepFake technology, WIMI plans to support holographic cloud platform service and 5G communication holographic application with a number of innovative systems.

As shown in the IPO prospectus of WIMI that the services of WIMI will be deeply combined with 5G. Under the cooperation of 5G with high rate and low delay, it makes the average transmission delay is about 6ms in terms of remote communication, data transmission as well as from system terminal to service server, which is much lower than 4G network transmission delay. It trully ensures the richness and diversity of holographic AR remote communication and data transmission without stuttering and low delay, and the richness and diversity of interaction in term of multi-terminal cooperation in different places. It makes the collaboration of port plus cloud more efficient. Based on 5G+AI face recognition technology and holographic AI DeepFake technology, the application of the enhanced mobile broadband (EMBB) and Internet of things (IOT) has made plenty of holographic services of the WIMI to be achieved with effective growth, such as holographic AR advertising business, holographic AR entertainment business, holographic interactive entertainment, holographic conference, holographic social contact, holographic communication, holographic home hologram and so on.

* Source: U.S. SEC – FORM F-1, WiMi Hologram Cloud Inc., Securities and Exchange Commission (SEC).

Media Contact

Name: Tim Wong
Email: bjoverseasnews@gmail.com
Tele: +86 10 89913328

SOURCE: WiMi

ReleaseID: 553950

KELOWNA, BC / ACCESSWIRE / July 30, 2019 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX), (the “Company” or “Lexaria”) an innovator in drug delivery platforms, reports on its existing technology licensees that have signed definitive contracts to use Lexaria’s revolutionary DehydraTECHTM absorption technology within their existing and emerging brands.

“The first half of 2019 delivered a period of unprecedented achievements for Lexaria,” said Chris Bunka, Chief Executive Officer. “We signed more license agreements than ever before in our Company’s history, many of which were larger in scope than anything previous. We also launched our brand-new business division Lexaria Nicotine which is disrupting nicotine delivery methods that already attracted one of the world’s largest nicotine companies, which has licensed our technology.”

Year to date 2019, Lexaria has announced:

1 new license agreement with *Altria Ventures Inc, an indirect wholly-owned subsidiary of Altria Group Inc. for oral nicotine products (note 1);
1 new CBD/hemp license to Nuka for beverages across the US;
2 new world-wide beverage licenses to Hill Street Beverages (except Mexico);
2 new Joint Manufacturing Production licenses with Hill Street Beverages for new jointly owned cannabis and CBD brands;
3 new licenses with others for CBD beverages and edible CBD ingredient/products across America.
1 new license for cannabis beverages in California;
1 new multi-state cannabis expansion license with Nuka Enterprises LLC (“Nuka”) for its 1906 Brands for 5 states total, and 2 new product categories

Lexaria now has 9 corporate licensees who are developing innovative beverages, edibles and oral products with their 11 licenses using the Company’s fully patented DehydraTECH absorption technology:

Company

Substance

Territory

Term

Category

Estimated Operations Launch

Altria Ventures Inc.

Nicotine

USA

Indefinite

Oral Products

TBD

Nukas’

1906-Brands

CBD/Hemp

USA

10-Year

Beverages

Q2/2020

Unamed

CBD/Hemp

USA

5-Year

Beverages

Q4/2019

Universal Hemp

CBD/Hemp

USA and Canada

5-Year

Dry food ingredients

Q1/2020

Nic’s Beverages

CBD/Hemp

USA

5-Year

Beverages

Q4/2019

Hill Street Beverage

CBD/Hemp

Global except Mexico

10-Year

Beverages

Q2/2000

Hill Street and Lexaria JV

CBD/Hemp

Global except Mexico

10-Year

Multiple

Q2/2020

Cannfections

Cannabis

Canada

7-Year

Chocolates and Candies

Q2/2020

Nuka’s 1906-Brands

Cannabis

OH, IL, MA, CO, MI

10-Yesr

Candies, Chocolates, Beverages

Q4/2019

Unamed

Cannabis

California

5 Year

Beverages

Q4/2019

Hill Street Beverages

Cannabis

Global except Mexico

10-Year

Beverages

Q1/2020

Hill Street and Lexaria Joint Venture

Cannabis

Global

10-Year

Multiple

Q2/2020

Based on these existing contracts, Lexaria expects to experience unprecedented revenue growth as we estimate many of our clients will commence operations in late 2019 and early 2020. Several of these clients are already planning and preparing for aggressive roll-outs and growth of their product lines. (Note that estimated operations start dates are Lexaria’s own estimates and may or may not reflect actual licensee results.)

Lexaria credits its recent commercial success mainly to its ever-growing body of scientific results evidencing the superior capabilities and power of its patented technologies. Recent 2019 technological advancements are the result of one of the industry’s most focused and productive R&D programs and hold promise for even higher levels of performance from new DehydraTECH innovations with even faster drug delivery into blood plasma and across the blood-brain-barrier.

In one recent animal study, as earlier announced, Lexaria’s latest patent-pending formulations delivered more than 1,900% more CBD into brain tissue than generic industry formulations and achieved peak blood levels more than 800% greater than those of concentration matched controls. In that same animal study, detection of CBD in the bloodstream began in as little as 2 minutes after dosing and peaked in as little as 45 minutes after dosing providing additional support that DehydraTECH enables rapid onset and offset in line with consumer preferences.

Lexaria expects to sign additional new definitive license agreements through the balance of 2019 and beyond as demand for its industry-leading technology continues, and it commends its family of existing licensees and partners that have already joined the Lexaria ecosystem with their exciting products and offerings powered by DehydraTECH.

*Note 1: The license with Altria Ventures Inc is with Lexaria Nicotine LLC, a separate business division of Lexaria Bioscience Corp.

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

www.lexariabioscience.com

For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp)

and on Facebook https://www.facebook.com/lexariabioscience/

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(250) 765-6424 ext. 202

Or

NetworkNewsWire (NNW)
www.NetworkNewsWire.com

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids, nicotine or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.

The CSE not the TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: Lexaria Bioscience Corp.

ReleaseID: 553899

Orchid Ventures closes the acquisition of GreenBloom Cannabis Co. Assets

IRVINE, CA / ACCESSWIRE / July 30, 2019 / Premium cannabis brand Orchid Ventures, Inc. (CSE: ORCD) (OTC PINK: ORVRF) announced today that it signed an amended and restated asset purchase agreement (originally announced on July 3, 2019) and completed the acquisition of certain assets of GreenBloom Cannabis Co., a vertically-integrated cannabis operator. Through the acquisition, Orchid Ventures will add, pending regulatory approval, five retail stores, two cultivation facilities, one distribution entity, and six brands to its operations. The integration of all GreenBloom Cannabis Co., staff and facilities will begin immediately.

Importantly, Orchid will control a sophisticated and quality supply-chain from seed to sale, cementing itself as a diverse and robust cannabis portfolio. As a combined entity, Orchid Ventures plans to develop a cultivation and processing facility that includes 300,000 square-feet of canopy and a 25,000 square-foot extraction facility.

“We are singularly focused on increasing revenues and building a more solidified supply chain in both California and Oregon,” said Corey Mangold, CEO of Orchid. “We’re pleased that this deal not only achieves those goals, but also builds the company’s market share, increases shareholder value, and strengthens the Orchid team overall to drive further successes.”

“This marks a significant milestone in the acquisition. Our joint efforts to merge operations begin now to immediately and fully integrate our professional teams,” said George Mattia, CEO of GreenBloom Cannabis. “Furthermore, the marriage of Orchid and GreenBloom allows access to GreenBloom’s resources to immediately streamline production and launch new and innovative product lines. The remainder of the assets involve regulatory license transfers and we are now collectively focused on furthering the growth of the combined organization while completing all license transfers to Orchid Ventures.”

Pursuant to the terms of the Definitive Agreement, in consideration for the Acquisition and upon closing thereof, the Company will pay an aggregate cash amount of US$10,000,000 to be paid out over the next 12 months, and issue 50,000,000 common shares at a deemed price of CA$0.50 per share (the “Payment Shares”). The Payment Shares will be subject to escrow conditions and/or resale restrictions as required by applicable securities laws and the policies of the CSE as well as additional voluntary hold periods agreed to by GreenBloom. Contingencies on share issuances and cash payments are tied to regulatory approval, successful license transfers and successful development accomplishments on the 300,000 square foot cultivation and manufacturing facility in California, as well as audited financial statements.

In connection with the initial closing of certain GreenBloom assets today, July 30, 2019, the Company issued 5,078,623 Payment Shares. Such Payment Shares are subject to a statutory hold period expiring December 1, 2019 as well as certain voluntary hold periods agreed to by GreenBloom. No cash consideration was payable in connection with today’s closing.

None of the securities to be issued pursuant to the Acquisition or the Warrant have been or will be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and any securities issued pursuant to the Acquisition and Warrant are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Rule 506(b) of Regulation D and/or Section 4(a)(2) of the U.S. Securities Act and applicable exemptions under state securities laws. In addition, the securities issued under an exemption from the registration requirements of the U.S. Securities Act will be “restricted securities” as defined under Rule 144(a)(3) of the U.S. Securities Act and will contain the appropriate restrictive legend as required under the U.S. Securities Act.

ABOUT ORCHID VENTURES, INC.

Orchid Ventures, Inc. is an Irvine, CA-based multi-state brand that launched in Oregon and California in August 2017 and has since developed a mass-market brand and loyal consumer following with its premium vape products. Orchid’s products lines are currently sold in 350+ dispensaries across California and Oregon and are handcrafted and designed for maximum flavor and overall enjoyment. The company’s proven processes and passion for what it does carry through into its products. The end result is an unparalleled experience for new and practiced cannabis users alike. Orchid plans to expand its brands into new national markets as well as global markets such as Latin America and Europe. With a continued focus on brand and intellectual property development, Orchid will execute strategic acquisitions to solidify an integrated cannabis manufacturing and distribution infrastructure with the goal of becoming a dominant premium cannabis brand in the United States. Orchid’s management brings significant branding, product development and distribution experience with a proven track record of scaling revenues, building value-generating partnerships and creating enterprise value. Learn more at https://orchidessentials.com/

ON BEHALF OF THE BOARD OF DIRECTORS – ORCHID VENTURES, INC.

Corey Mangold
CEO and Director
investors@orchidessentials.com

Investor Relations
Antonio Cruz
(949) 769-3859
a.cruz@orchidventures.com

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE

Safe Harbor Statement

Except for historical information contained herein, statements in this release may be forward-looking and made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Orchid Ventures, Inc. and Orchid Essentials (collectively, the “Company”) or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company’s Canadian securities regulatory filings with sedar.com, Factors which could cause actual results to differ materially from these forward-looking statements include such factors as (i) the development and protection of our brands and other intellectual property, (ii) the need to raise capital to meet business requirements, (iii) significant fluctuations in marketing expenses, (iv) the ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of our products and services, (v) the Company’s ability to conduct the business if there are changes in laws, regulations, or government policies related to cannabis, (vi) management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and (vii) other information that may be detailed from time to time in the Company’s Canadian securities regulatory filings with sedar.com. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Orchid Ventures, Inc.

ReleaseID: 553943